International Stem Cell (ISCO) is an early-stage cell therapy company currently in clinical trials to treat Parkinson’s disease (PD). In November, the company presented interim six-month results from the first cohort of four patients in its Phase I trial of ISC-hpNSC in PD. Positive signals were seen in a variety of measures, which include daily living, mobility, depression and compulsive disorders.
14 May 2018
Moving forward in Parkinsons and TBI
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Moving forward in Parkinsons and TBI
- Published:
14 May 2018 -
Author:
Maxim Jacobs -
Pages:
11
International Stem Cell (ISCO) is an early-stage cell therapy company currently in clinical trials to treat Parkinson’s disease (PD). In November, the company presented interim six-month results from the first cohort of four patients in its Phase I trial of ISC-hpNSC in PD. Positive signals were seen in a variety of measures, which include daily living, mobility, depression and compulsive disorders.